Related Experiment Video

Updated: Jul 12, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist

David A Johnson1

  • 1Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA.

Reviews in Cardiovascular Medicine
|December 6, 2007
PubMed

Insights

Cardiologists commonly prescribe antiplatelet agents alongside NSAIDs, increasing upper gastrointestinal risks. Understanding these risks is crucial for preventing ulcer complications with appropriate co-therapy.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Cardiovascular disease management frequently involves antiplatelet/antithrombotic agents like aspirin or clopidogrel.
  • Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) for other conditions is common among patients on these agents.
  • Combined therapy presents significant upper gastrointestinal (UGI) risks, including ulceration and bleeding.

Purpose of the Study:

  • To highlight the increased upper gastrointestinal risks associated with combined antiplatelet/antithrombotic and NSAID therapy.
  • To emphasize the importance of cardiologists understanding these UGI risk profiles.
  • To advocate for the evaluation of preventive anti-ulcer co-therapy in at-risk patients.

Main Methods:

  • Review of current clinical practices in cardiovascular disease treatment.
  • Analysis of known gastrointestinal risks associated with antiplatelet agents and NSAIDs.
  • Discussion of risk stratification and preventive strategies.

Main Results:

  • The concurrent use of antiplatelet/antithrombotic agents and NSAIDs significantly elevates the risk of upper gastrointestinal injury.
  • Specific agents like low-dose aspirin and clopidogrel, when combined with NSAIDs, contribute to this heightened risk.
  • Lack of awareness or underestimation of these risks can lead to serious UGI complications.

Conclusions:

  • Cardiologists must be fully aware of the upper gastrointestinal risk profiles associated with combined antiplatelet and NSAID therapy.
  • Proactive patient evaluation for preventive co-therapy with anti-ulcer medication is essential.
  • Implementing preventive strategies can mitigate serious gastrointestinal complications in patients undergoing cardiovascular treatment.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...